Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: March 2014

Tomorrow! HINJ and NEHI to Host ‘Innovation in an Era of Payment Reform’ Forum on April 1

New Brunswick, NJ, March 31, 2014 — The HealthCare Institute of New Jersey (HINJ) and NEHI (The Network for Excellence in Health Innovation) will host “Innovation in an Era of Payment Reform: How Will New Jersey’s Life Sciences Companies Respond?” on Tuesday, April 1 from 8:30 to 11:30 a.m. at the Crowne Plaza Monroe South Brunswick in Monroe Township, NJ.

Health care payment reform is already transforming the way health care providers deliver care throughout the United States.  Payment reform will not only influence the quality and cost of health care, it will also impact innovation in New Jersey’s historically dynamic life sciences sector.  Continue reading

Rutgers Cancer Institute Makes Advances in Treatment of Women’s Reproductive Cancers

New Brunswick, NJ, March 27, 2014 —According to the Centers for Disease Control and Prevention, nearly 84,000 women each year are diagnosed with a gynecologic cancer, and 29,000 die from one of these diseases.  

Physician scientists at Rutgers Cancer Institute of New Jersey continue to make great strides in this area, advancing scientific and clinical knowledge to combat cervical, ovarian, uterine, vaginal and other cancers of the reproductive system.

Lorna Rodriguez, MD, PhD, a gynecologic oncologist and director of the Cancer Institute of New Jersey’s precision medicine initiative, gave an oral presentation at the Society of Gynecologic Oncology’s (SGO) 45th Annual Meeting on Women’s Cancer this past week that focuses on recurrent or advanced stage cervical cancer.  Continue reading

NJIT to Host TEDxNJIT on ‘Transformations’ April 3 Live and Via Web

Newark, NJ, March 27, 2014 — New Jersey Institute of Technology (NJIT) will host TEDxNJIT on the theme of Transformations on Thursday, April 3.  The event will be held from 5:00 to 9:00 p.m. at the Jim Wise Theater on NJIT’s campus in Newark as well as via the Web at www.tedxnjit.com beginning at 6:00 p.m.

The independently organized event, licensed by TED, will focus on transformations and will feature leaders in the field.  It will bring together faculty and students to share their passion for innovation. Continue reading

NJ Big Data Alliance to Host Inaugural Symposium, ‘Partnership in Big Data,’ April 23 at Rutgers

New Brunswick, NJ, March 25, 2014 — The New Jersey Big Data Alliance (NJBDA) will launch officially at its inaugural symposium, entitled “Partnerships in Big Data:  Pathways to Transformative Innovation in New Jersey,” on Wednesday, April 23 from 8:15 a.m. to 5:00 p.m. at Rutgers’ Livingston Hall in the Livingston Student Center, 88 Joyce Kilmer Avenue, Piscataway.

The New Jersey Big Data Alliance is a consortium of higher education institutions that was initiated by the Rutgers Office of Research and Economic Development to address the challenges posted by the deluge of digital data.  Continue reading

Rutgers Cancer Institute and Univ. of Wisconsin Carbone Cancer Center Awarded $4.25 Million Grant to Develop Innovative Clinical Trials

New Brunswick, NJ, March 21, 2014 — Precision medicine, or the movement to ‘personalize’ cancer treatments, has grown significantly over the past few years, with researchers from large universities and cancer centers from across the nation making advances in identifying targeted therapies and understanding what drives them.

Aiming to further build on that momentum with the development of innovative early-phase clinical trials examining genomic and therapeutic biomarkers is Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey.

Dr. DiPaola, who was just awarded a competitive $4.25 million grant (UM1CA186716) by the National Cancer Institute (NCI) of the National Institutes of Health to support the precision experimental therapeutics endeavor, will collaborate with investigators from the University of Wisconsin Carbone Cancer Center on the research that will have a nationwide reach. Continue reading

Billionaires with Big Ideas Are Privatizing American Science

New York, NY, March 17, 2014 — According to The New York Times, American science, long a source of national power and pride, is increasingly becoming a private enterprise. 

In Washington, budget cuts have left the nation’s research complex reeling.  Labs are closing.  Scientists are being laid off.  Projects are being put on the shelf, especially in the risky, freewheeling realm of basic research.  Yet from Silicon Valley to Wall Street, science philanthropy is hot, as many of the richest Americans seek to reinvent themselves as patrons of social progress through science research.  

The result is a new calculus of influence and priorities that the scientific community views with a mix of gratitude and trepidation. Continue reading

NJ Quality Health Care Quality Institute Partners to Present ‘Big Data and Health’ Conference April 4

Pennington, NJ, March 14, 2014 — The New Jersey Health Care Quality Institute, in partnership with the Woodrow Wilson School of Public and International Affairs and The Nicholson Foundation, will host “Big Data and Health: Implications for New Jersey’s Health Care System,” on Friday April 4, 2014.

The day-long event will be held at Dodds Auditorium Robertson Hall in Princeton, NJ.

Designed to promote an understanding of big data and health, this conference will highlight ways that “big data” techniques are currently being used in the health sector across the county, explore their potential to improve health care in New Jersey, and examine the potential privacy risks and cost implications. Continue reading

BioPharma Research Council to Present ‘D2D: Data to Drugs and Diagnostics’ June 11-12

Edison, NJ, March 14, 2014 — The BioPharma Research Council will present “D2D: Data to Drugs and Diagnostics” on June 11 and 12 at the New Jersey Convention and Exposition Center in Edison NJ, 08837.

D2D: Data to Drugs and Diagnostics (D2D) is a Congress, a Codefest and a Trade Show to bring together biopharma researchers, drug and device developers, biomedical engineers, and IT professionals:

The D2D Congress will focus on enabling IT tools and solutions driving innovation throughout the therapeutics life cycle, including translation into clinical practice. Continue reading

Commentary: Life Sciences Sector Supports Good Jobs in New Jersey

Cherry Hill, NJ, March 13, 2014The Courier-Post on March 11 published the following commentary authored by Raymond M. Pocino, vice president and eastern regional manager of the Laborers’ International Union of North America.

*     *     *

New Jersey is home to nearly 30 scientists and engineers per square mile — more than any other state.

But it doesn’t take 10 years of higher education to understand the value of the life sciences and pharmaceutical industry in New Jersey. In fact, a federally approved apprenticeship program — the kind that produces the Garden State’s carpenters, heavy-equipment operators, ironworkers and construction craft laborers — might be all you need.

As a member of the Laborers’ International Union of North America, I’ve seen how the pharmaceutical industry stimulates economic growth — even for the construction industry.

The pharmaceutical sector and its supporting industries have long been significant contributors to New Jersey’s economy. Policymakers should work to keep it that way. Continue reading

Rutgers Cancer Institute’s Dr. Richard Drachtman Tapped for National Cancer Institute Board

New Brunswick, NJ, March 13, 2014 — Richard Drachtman, MD, interim chief of pediatric hematology/oncology at Rutgers Cancer Institute of New Jersey has been appointed as Vice Chair of the National Cancer Institute (NCI) Pediatric Central Institutional Review Board (PedCIRB).

Dr. Drachtman, who also is a professor of pediatrics at Rutgers Robert Wood Johnson Medical School, was selected based on his experience as an NCI PedCIRB member, having served on the panel since 2009.  He also was selected based on his knowledge of current clinical oncology practice and experience working with NCI Cooperative Groups. Continue reading